Last edition
News about Drug Discovery & Development
Sun Pharma Recalls 144 Bottles of Anti-Depression Drug from US Market
Sun Pharmaceutical Industries Inc has recalled 144 bottles of a generic anti-depression medicine from the US market due to a manufacturing issue, according to the U.S. Food and Drug Administration (FDA).
Drug Discovery & Development | 23/10/2023 | By Manvi | 480
Glenmark Pharmaceuticals Gets ANDA Approval for Apremilast Tablets, 10 mg, 20 mg and 30 mg
According to IQVIATM sales data for the 12-month period ending August 2023, the Otezla® Tablets, 10 mg, 20 mg, and 30 mg market2 achieved annual sales of approximately USD 3.7 billion.
Drug Discovery & Development | 18/10/2023 | By Manvi | 834
Venus Remedies Gets Marketing Approval for Six Chemotherapy Drugs from Philippines
Venus Remedies has secured marketing authorisation for bortezomib, cisplatin, doxorubicin, docetaxel, flurouracil and paclitaxel from the Philippines, thus making it a significant market for the company from the ASEAN region.
Drug Discovery & Development | 18/10/2023 | By Manvi | 651
DST Grants INR 13.69 Cr to GITAM for Drug Discovery Centre
The grant, conferred through the Promotion of University Research and Scientific Excellence (PURSE) program, will support the procurement of new equipment, research costs, manpower, conduct of workshops/summer schools etc.
Drug Discovery & Development | 16/10/2023 | By Manvi | 852
Shilpa Medicare Launches ORAAL for the Treatment of Oral Mucositis
ORAAL, a substantial advancement in Oral Mucositis management, has been accepted and approved by the Indian Dental Association.
Drug Discovery & Development | 16/10/2023 | By Manvi | 1318
Fujitsu Limited and the HPC- and AI-driven Drug Development Platform Division of the RIKEN Center for Computational Science announced that they have developed an AI drug discovery technology that can predict structural changes of proteins from electron microscope images as a 3D density map in wide range by utilizing generative AI in January 2023.
Drug Discovery & Development | 11/10/2023 | By Manvi | 738
Approval of this product under the PEPFAR program completes Strides' qualification to all major markets and donor programs including Global Fund and South Africa.
Drug Discovery & Development | 19/09/2023 | By Manvi | 494
Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day.
Drug Discovery & Development | 19/09/2023 | By Manvi | 739
Strides Pharma Gets USFDA Tentative Nod for Generic HIV Treatment Drug
Strides Pharma Science Ltd said its wholly-owned subsidiary Strides Pharma Global Pte Ltd, Singapore, has received tentative approval from the US health regulator for generic Dolutegravir tablets used in the treatment of HIV.
Drug Discovery & Development | 15/09/2023 | By Manvi | 605
Sun Pharma and Pharmazz Enter into Licensing Agreement for Introducing Tyvalzi in India
As per agreement terms, Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi™ (Sovateltide). Pharmazz will be entitled to upfront and milestone payments, including royalties.
Drug Discovery & Development | 15/09/2023 | By Manvi | 1543
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy